Biotech Values

[St_armands_man]

>The cfo leaving shouldn't bother you because there weren't any revenues to screw around with.<

DNDN doesn’t have any material revenues either, and yet the announcement of the CFO’s departure there was a harbinger of poor performance for the stock.

As previously noted, among all of the top executives in a biotech company, the CFO has the least to gain and the most to lose by sticking around when there are problems not fully known to investors.

As a CFO myself, I concur with your above statement (it usually applies to any publically traded company - not just biotech).